FANSIDAR
LOE ApproachingNDAORALTABLETPriority Review
Approved
Oct 1981
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FANSIDAR is an oral small-molecule tablet approved in 1981 by Roche for treating autoimmune disease and lymphoproliferative disorders. The mechanism of action and pharmacologic class are not publicly detailed in available data. It represents a legacy therapeutic asset in Roche's portfolio with a long market history.
LOE Approaching
This product is approaching loss of exclusivity with moderate competitive pressure (30%), signaling a shrinking brand team and transition focus toward lifecycle extension or managed decline.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on FANSIDAR in a LOE-approaching phase offers limited career growth but valuable experience in managed decline, generic transition strategy, and portfolio rationalization. This is a role best suited to early-career professionals building foundational skills or specialists in lifecycle management rather than high-growth brand acceleration.
Brand ManagerField Sales
Worked on FANSIDAR at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.